Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0NT6P
|
|||
| Drug Name |
MK8242
|
|||
| Indication | Acute myeloid leukaemia [ICD-11: 2A60] | Phase 2 | [1] | |
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 1 | [2] | ||
| Company |
Merck
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01463696) Study of Safety and Pharmacokinetics of MK-8242 in Participants With Advanced Solid Tumors (P07650). U.S. National Institutes of Health. | |||
| REF 2 | Small molecules, big targets: drug discovery faces the protein-protein interaction challenge.Nat Rev Drug Discov. 2016 Aug;15(8):533-50. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.